<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2310-0265</journal-id>
<journal-title><![CDATA[Revista CON-CIENCIA]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Cs.Farm. y Bioq]]></abbrev-journal-title>
<issn>2310-0265</issn>
<publisher>
<publisher-name><![CDATA[Facultad de Ciencias Farmacéuticas y BioquímicasUniversidad Mayor de San Andrés]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2310-02652023000100037</article-id>
<article-id pub-id-type="doi">10.53287/khqe6113xv45x</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Inhibición de enzimas fosfolipasas A2 de venenos totales de serpientes como estrategia en la búsqueda de nuevos fármacos]]></article-title>
<article-title xml:lang="en"><![CDATA[Enzyme phospholipase A2 inhibition from snake venoms as strategy to search for new drug]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Barrera-Luna]]></surname>
<given-names><![CDATA[Geovanny]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cazar]]></surname>
<given-names><![CDATA[María-Elena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,aff1  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,aff2  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2023</year>
</pub-date>
<volume>11</volume>
<numero>1</numero>
<fpage>37</fpage>
<lpage>53</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_arttext&amp;pid=S2310-02652023000100037&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_abstract&amp;pid=S2310-02652023000100037&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_pdf&amp;pid=S2310-02652023000100037&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  Los fármacos antiinflamatorios no esteroideos (AINEs) son ampliamente utilizados para la terapia del dolor, a pesar de sus efectos secundarios que ocurren a nivel renal, estomacal y coagulatorio. Las fosfolipasas A2 (PLA2) presentes en los venenos de serpientes, abejas e incluso en el organismo humano, son responsables de varios procesos fisiológicos y patológicos. Las enzimas hidrolizan fosfolípidos de membrana liberando ácido araquidónico, un precursor de los eicosanoides pro-inflamatorios, los cuales originan mediadores de la inflamación.  Objetivo:  El propósito de este trabajo es revisar nuevas moléculas capaces de bloquear la escisión de los fosfolípidos de membrana por acción de las PLA2, evitando la formación de mediadores de inflamación.  Metodología:  Se realizó una revisión bibliográfica de estudios publicados desde 2011 a 2021, que reportan compuestos con actividad inhibitoria frente a PLA2. El potencial de los estudios de relación estructura actividad se discute como estrategia para encontrar compuestos activos ante PLA2.  Resultados: Se revisaron 26 estudios que incluyen compuestos naturales y sintéticos y se recopilaron 93 moléculas con actividad inhibitoria, destacando su potencial como inhibidores de PLA2.  Conclusiones:  La actividad inhibitoria de los compuestos revisados podría estar asociada a los patrones de sustitución en el anillo bencénico de las moléculas. La evaluación de características moleculares relevantes en la inhibición de PLA2 puede guiar a la identificación de candidatos para síntesis de nuevos inhibidores enzimáticos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for pain therapy, despite its side effects in renal, stomach and coagulant systems. Phospholipases A2 (PLA2) enzymes, present in snakes and bees&#8217; venoms, and even in the human organism, are responsible for several physiological and pathological processes. These enzymes hydrolyze membrane phospholipids, releasing arachidonic acid, a precursor of pro-inflammatory eicosanoids, which give rise to inflammatory mediators.  Objective:  The aim of the present work is to review new molecules able to block the cleavage of membrane phospholipids by the action of phospholipases A2, preventing the formation of inflammatory mediators.  Methodology:  A bibliographic revision from literature published from 2011 to 2021 focused on PLA2 inhibitors was carried out. The potential of structure-activity relationship studies is discussed as a strategy to find active compounds against PLA2.  Results:  26 studies including natural and synthetic compounds were reviewed and data from 93 molecules with inhibitory activity were collected, highlighting its potential as PLA2 inhibitors.  Conclusion: The inhibitory activity of the reviewed compounds could be associated with the substitution patterns in the benzene ring of the molecules. The evaluation of molecular moieties with relevant capacity to inhibit PLA2 will lead to the identification of candidates for synthesis of new enzymes inhibitors.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Fosfolipasas A2]]></kwd>
<kwd lng="es"><![CDATA[inflamación]]></kwd>
<kwd lng="es"><![CDATA[actividad enzimática]]></kwd>
<kwd lng="es"><![CDATA[inhibición]]></kwd>
<kwd lng="en"><![CDATA[Phospholipase A2]]></kwd>
<kwd lng="en"><![CDATA[inflammation]]></kwd>
<kwd lng="en"><![CDATA[enzymatic activity]]></kwd>
<kwd lng="en"><![CDATA[inhibition]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alam]]></surname>
<given-names><![CDATA[M. I.]]></given-names>
</name>
<name>
<surname><![CDATA[Alam]]></surname>
<given-names><![CDATA[M. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Alam]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Nargotra]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Taneja]]></surname>
<given-names><![CDATA[S. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Koul]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship]]></article-title>
<source><![CDATA[European journal of medicinal chemistry]]></source>
<year>2016</year>
<numero>114</numero>
<issue>114</issue>
<page-range>209-19</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alasmary]]></surname>
<given-names><![CDATA[F. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Alnahdi]]></surname>
<given-names><![CDATA[F. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Ben Bacha]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[El-Araby]]></surname>
<given-names><![CDATA[A. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Moubayed]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Alafeefy]]></surname>
<given-names><![CDATA[A. M.]]></given-names>
</name>
<name>
<surname><![CDATA[El-Araby]]></surname>
<given-names><![CDATA[M. E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New quinoxalinone inhibitors targeting secreted phospholipase A2 and &#945;-glucosidase]]></article-title>
<source><![CDATA[Journal of enzyme inhibition and medicinal chemistry]]></source>
<year>2017</year>
<volume>32</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1143-51</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anilkumar]]></surname>
<given-names><![CDATA[N. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Sundaram]]></surname>
<given-names><![CDATA[M. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Mohan]]></surname>
<given-names><![CDATA[C. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Rangappa]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Bulusu]]></surname>
<given-names><![CDATA[K. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Fuchs]]></surname>
<given-names><![CDATA[J. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Girish]]></surname>
<given-names><![CDATA[K. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Bender]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Rangappa]]></surname>
<given-names><![CDATA[K. S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A one pot synthesis of novel bioactive tri-substitute-condensed-imidazopyridines that targets snake venom phospholipase a2]]></article-title>
<source><![CDATA[PloS one]]></source>
<year>2015</year>
<volume>10</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Batsika]]></surname>
<given-names><![CDATA[C. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Gerogiannopoulou]]></surname>
<given-names><![CDATA[A.-D. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Mantzourani]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Vasilakaki]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Kokotos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[The design and discovery of phospholipase A2 inhibitors for the treatment of inflammatory diseases]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bukhari]]></surname>
<given-names><![CDATA[S. N. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Lauro]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Jantan]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Bifulco]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Amjad]]></surname>
<given-names><![CDATA[M. W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacological evaluation and docking studies of &#945;, &#946;-unsaturated carbonyl based synthetic compounds as inhibitors of secretory phospholipase A2, cyclooxygenases, lipoxygenase and proinflammatory cytokines]]></article-title>
<source><![CDATA[Bioorganic &amp; medicinal chemistry]]></source>
<year>2014</year>
<volume>22</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>4151-61</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calvete]]></surname>
<given-names><![CDATA[J. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Snake venomics: From the inventory of toxins to biology]]></article-title>
<source><![CDATA[Toxicon]]></source>
<year>2013</year>
<numero>75</numero>
<issue>75</issue>
<page-range>44-62</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carter]]></surname>
<given-names><![CDATA[R. W.]]></given-names>
</name>
<name>
<surname><![CDATA[Gerardo]]></surname>
<given-names><![CDATA[C. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Samuel]]></surname>
<given-names><![CDATA[S. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Kotehal]]></surname>
<given-names><![CDATA[S. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Mukherjee]]></surname>
<given-names><![CDATA[P. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Shirazi]]></surname>
<given-names><![CDATA[F. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Akpunonu]]></surname>
<given-names><![CDATA[P. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Bammigatti]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Bhalla]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The BRAVO clinical study protocol: Oral varespladib for inhibition of secretory phospholipase A2 in the treatment of snakebite envenoming]]></article-title>
<source><![CDATA[toxins]]></source>
<year>2023</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>22</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carvalho]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Xavier]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Resende]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Marcussi]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Marangoni]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Stábeli]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Calderon]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Snake venom PLA2s inhibitors isolated from Brazilian plants: Synthetic and natural molecules]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castañeda]]></surname>
<given-names><![CDATA[I. H.]]></given-names>
</name>
<name>
<surname><![CDATA[Pereañez]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Jios]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Substituted thiobenzoic acid S-benzyl esters as potential inhibitors of a snake venom phospholipase A2: Synthesis, spectroscopic and computational studies]]></article-title>
<source><![CDATA[Journal of Molecular Structure]]></source>
<year>2012</year>
<numero>1028</numero>
<issue>1028</issue>
<page-range>7-12</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chinnasamy]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Selvaraj]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Selvaraj]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Kaushik]]></surname>
<given-names><![CDATA[A. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Kaliamurthi]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[S. K.]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[D.-Q]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combining in silico and in vitro approaches to identification of potent inhibitor against phospholipase A2 (PLA2)]]></article-title>
<source><![CDATA[International journal of biological macromolecules]]></source>
<year>2020</year>
<numero>144</numero>
<issue>144</issue>
<page-range>53-66</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Da Silva]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Calgarotto]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Maso]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Damico]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Baldasso]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Veber]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Villar]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Comar Jr]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular modeling and inhibition of phospholipase A2 by polyhydroxy phenolic compounds]]></article-title>
<source><![CDATA[European Journal of Medicinal Chemistry]]></source>
<year>2009</year>
<volume>44</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>312-21</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Alvarenga]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Barosa]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Demuner]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Parreira]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Ribeiro]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Marcussi]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Resende]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Granjeiro]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Synthesis and evaluation of sesquiterpene lactone inhibitors of phospholipase A2 from Bothrops jararacussu]]></article-title>
<source><![CDATA[Toxicon]]></source>
<year>2011</year>
<volume>57</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>100-8</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Angelis]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Maria Tata]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analgesic effects mediated by muscarinic receptors: Mechanisms and pharmacological approaches]]></article-title>
<source><![CDATA[Central Nervous System Agents in Medicinal Chemistry]]></source>
<year>2016</year>
<volume>16</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>218-26</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dennis]]></surname>
<given-names><![CDATA[E. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Cao]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Hsu]]></surname>
<given-names><![CDATA[Y.-H.]]></given-names>
</name>
<name>
<surname><![CDATA[Magrioti]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Kokotos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phospholipase A2 enzymes: Physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention]]></article-title>
<source><![CDATA[Chemical reviews]]></source>
<year>2011</year>
<volume>111</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>6130-85</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[El-Sayed]]></surname>
<given-names><![CDATA[N. N.]]></given-names>
</name>
<name>
<surname><![CDATA[Almaneai]]></surname>
<given-names><![CDATA[N. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Ben Bacha]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Obeed]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmad]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Abdulla]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Alafeefy]]></surname>
<given-names><![CDATA[A. M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Synthesis and evaluation of anticancer, antiphospholipases, antiproteases, and antimetabolic syndrome activities of some 3 H-quinazolin-4-one derivatives]]></article-title>
<source><![CDATA[Journal of enzyme inhibition and medicinal chemistry]]></source>
<year>2019</year>
<volume>34</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>672-83</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Filkin]]></surname>
<given-names><![CDATA[S. Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Lipkin]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Fedorov]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phospholipase superfamily: Structure, functions, and biotechnological applications]]></article-title>
<source><![CDATA[Biochemistry]]></source>
<year>2020</year>
<volume>85</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>177-95</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fonseca]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Baldissera Jr]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Camargo]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Antunes]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Diz-Filho]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Corrêa]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Beriam]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Toyama]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Cotrim]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Toyama]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of the synthetic coumarin, ethyl 2-oxo-2H-chromene-3-carboxylate, on activity of Crotalus durissus ruruima sPLA2 as well as on edema and platelet aggregation induced by this factor]]></article-title>
<source><![CDATA[Toxicon]]></source>
<year>2010</year>
<volume>55</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1527-30</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harvey]]></surname>
<given-names><![CDATA[A. L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Toxins and drug discovery]]></article-title>
<source><![CDATA[Toxicon]]></source>
<year>2014</year>
<numero>92</numero>
<issue>92</issue>
<page-range>193-200</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hui]]></surname>
<given-names><![CDATA[D. Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phospholipase A2 enzymes in metabolic and cardiovascular diseases]]></article-title>
<source><![CDATA[Current opinion in lipidology]]></source>
<year>2012</year>
<volume>23</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>235</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kokotou]]></surname>
<given-names><![CDATA[M. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Limnios]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Nikolaou]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Psarra]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Kokotos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhibitors of phospholipase A2 and their therapeutic potential: An update on patents (2012-2016)]]></article-title>
<source><![CDATA[Expert opinion on therapeutic patents]]></source>
<year>2017</year>
<volume>27</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>217-25</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Magrioti]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Kokotos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phospholipase A2 inhibitors for the treatment of inflammatory diseases: A patent review (2010-present)]]></article-title>
<source><![CDATA[Expert Opinion on Therapeutic Patents]]></source>
<year>2013</year>
<volume>23</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>333-44</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Melima-Hage]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Sampaio]]></surname>
<given-names><![CDATA[S. V.]]></given-names>
</name>
<name>
<surname><![CDATA[Taft]]></surname>
<given-names><![CDATA[C. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phospholipase A2 inhibitors isolated from medicinal plants: Alternative treatment against snakebites]]></article-title>
<source><![CDATA[Mini Rev Med Chem]]></source>
<year>2013</year>
<volume>13</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1348-56</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mohamed]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[V Shivaprasad]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[M Jameel]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[A Shekar]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[S Vishwanath]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neutralization of local toxicity induced by vipera russelli phospholipase A2 by lipophilic derivative of ascorbic acid]]></article-title>
<source><![CDATA[Current topics in medicinal chemistry]]></source>
<year>2011</year>
<volume>11</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>2531-9</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muthusamy]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Chinnasamy]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Nagarajan]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Sivaraman]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Computational and in vitro insights on snake venom phospholipase A2 inhibitor of phytocompound ikshusterol3-O-glucoside of Clematis gouriana Roxb. Ex DC]]></article-title>
<source><![CDATA[Journal of Biomolecular Structure and Dynamics]]></source>
<year>2018</year>
<volume>36</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>4197-208</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muthusamy]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Chinnasamy]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Nagarajan]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Sivaraman]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Chinnasamy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Isolation and characterization of bioactive compounds of Clematis gouriana Roxb. Ex DC against snake venom phospholipase A2 (PLA2) computational and in vitro insights]]></article-title>
<source><![CDATA[Journal of Biomolecular Structure and Dynamics]]></source>
<year>2017</year>
<volume>35</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1936-49</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nargotra]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Alam]]></surname>
<given-names><![CDATA[M. I.]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmed]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Bhagat]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Taneja]]></surname>
<given-names><![CDATA[S. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Qazi]]></surname>
<given-names><![CDATA[G. N.]]></given-names>
</name>
<name>
<surname><![CDATA[Koul]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In silico identification of viper phospholipaseA2 inhibitors: Validation by in vitro, in vivo studies]]></article-title>
<source><![CDATA[Journal of molecular modeling]]></source>
<year>2011</year>
<volume>17</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>3063-73</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nikolaou]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Kokotou]]></surname>
<given-names><![CDATA[M. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Vasilakaki]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Kokotos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases A2]]></article-title>
<source><![CDATA[Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids]]></source>
<year>2019</year>
<volume>1864</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>941-56</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Novo Belchor]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Hessel Gaeta]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Fabri Bittencourt Rodrigues]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos da Cruz Costa]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[de Oliveira Toyama]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Domingues Passero]]></surname>
<given-names><![CDATA[L. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Dalastra Laurenti]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Hikari Toyama]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of rhamnetin as an inhibitor of the pharmacological effect of secretory phospholipase A2]]></article-title>
<source><![CDATA[Molecules]]></source>
<year>2017</year>
<volume>22</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1441</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pedada]]></surname>
<given-names><![CDATA[S. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Yarla]]></surname>
<given-names><![CDATA[N. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Tambade]]></surname>
<given-names><![CDATA[P. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Dhananjaya]]></surname>
<given-names><![CDATA[B. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Bishayee]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Arunasree]]></surname>
<given-names><![CDATA[K. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Philip]]></surname>
<given-names><![CDATA[G. H.]]></given-names>
</name>
<name>
<surname><![CDATA[Dharmapuri]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Aliev]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Putta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Synthesis of new secretory phospholipase A2-inhibitory indole containing isoxazole derivatives as anti-inflammatory and anticancer agents]]></article-title>
<source><![CDATA[European journal of medicinal chemistry]]></source>
<year>2016</year>
<numero>112</numero>
<issue>112</issue>
<page-range>289-97</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pereañez]]></surname>
<given-names><![CDATA[J. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Patiño]]></surname>
<given-names><![CDATA[A. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Núñez]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Osorio]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The biflavonoid morelloflavone inhibits the enzymatic and biological activities of a snake venom phospholipase A2]]></article-title>
<source><![CDATA[Chemico-biological interactions]]></source>
<year>2014</year>
<numero>220</numero>
<issue>220</issue>
<page-range>94-101</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quach]]></surname>
<given-names><![CDATA[N. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Arnold]]></surname>
<given-names><![CDATA[R. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Cummings]]></surname>
<given-names><![CDATA[B. S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Secretory phospholipase A2 enzymes as pharmacological targets for treatment of disease]]></article-title>
<source><![CDATA[Biochemical pharmacology]]></source>
<year>2014</year>
<volume>90</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>338-48</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sales]]></surname>
<given-names><![CDATA[T. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Marcussi]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Da Cunha]]></surname>
<given-names><![CDATA[E. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Kuca]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Ramalho]]></surname>
<given-names><![CDATA[T. C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Can inhibitors of snake venom phospholipases A2 lead to new insights into anti-inflammatory therapy in humans? A theoretical study]]></article-title>
<source><![CDATA[Toxins]]></source>
<year>2017</year>
<volume>9</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>341</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shridas]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Zahoor]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Forrest]]></surname>
<given-names><![CDATA[K. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Layne]]></surname>
<given-names><![CDATA[J. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Webb]]></surname>
<given-names><![CDATA[N. R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Group X secretory phospholipase A2 regulates insulin secretion through a cyclooxygenase-2-dependent mechanism]]></article-title>
<source><![CDATA[Journal of Biological Chemistry]]></source>
<year>2014</year>
<volume>289</volume>
<numero>40</numero>
<issue>40</issue>
<page-range>27410-7</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<collab>Stability Investigators</collab>
<article-title xml:lang=""><![CDATA[Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease]]></article-title>
<source><![CDATA[The New England Journal of Medicine]]></source>
<year>2014</year>
<volume>370</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1702-11</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Su]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Presynaptic effects of snake venom toxins which have phospholipase A2 activity (&#946;-bungarotoxin, taipoxin, crotoxin)]]></article-title>
<source><![CDATA[Toxicon]]></source>
<year>1984</year>
<volume>22</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>631-40</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tasoulis]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Isbister]]></surname>
<given-names><![CDATA[G. K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A review and database of snake venom proteomes]]></article-title>
<source><![CDATA[Toxins]]></source>
<year>2017</year>
<volume>9</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>290</page-range></nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Toyama]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Marangoni]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Diz-Filho]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Toyama]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of umbelliferone (7-hydroxycoumarin, 7-HOC) on the enzymatic, edematogenic and necrotic activities of secretory phospholipase A2 (sPLA2) isolated from Crotalus durissus collilineatus venom]]></article-title>
<source><![CDATA[Toxicon]]></source>
<year>2009</year>
<volume>53</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>417-26</page-range></nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Umar]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Abubakar]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Ibrahim]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Sallau]]></surname>
<given-names><![CDATA[B. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Natasha]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Isolation of phospholipase A2 inhibitor from Cryptolepis oblongifolia (Meins) Schltr]]></article-title>
<source><![CDATA[J Nat Sci Res]]></source>
<year>2014</year>
<volume>4</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>63-7</page-range></nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Utkin]]></surname>
<given-names><![CDATA[Y. N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Animal venom studies: Current benefits and future developments]]></article-title>
<source><![CDATA[World journal of biological chemistry]]></source>
<year>2015</year>
<volume>6</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>28</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vasilakaki]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Barbayianni]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Leonis]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Papadopoulos]]></surname>
<given-names><![CDATA[M. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Mavromoustakos]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Gelb]]></surname>
<given-names><![CDATA[M. H.]]></given-names>
</name>
<name>
<surname><![CDATA[Kokotos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development of a potent 2-oxoamide inhibitor of secreted phospholipase A2 guided by molecular docking calculations and molecular dynamics simulations]]></article-title>
<source><![CDATA[Bioorganic &amp; medicinal chemistry]]></source>
<year>2016</year>
<volume>24</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1683-95</page-range></nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xiao]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Pan]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Liao]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Snake venom PLA2, a promising target for broad-spectrum antivenom drug development]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B42">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ximenes]]></surname>
<given-names><![CDATA[R. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Alves]]></surname>
<given-names><![CDATA[R. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[T. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Araújo]]></surname>
<given-names><![CDATA[R. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Silveira]]></surname>
<given-names><![CDATA[E. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Rabello]]></surname>
<given-names><![CDATA[M. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Hernandes]]></surname>
<given-names><![CDATA[M. Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Soares]]></surname>
<given-names><![CDATA[V. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Bristot]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Pires]]></surname>
<given-names><![CDATA[C. L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Harpalycin 2 inhibits the enzymatic and platelet aggregation activities of PrTX-III, a D49 phospholipase A 2 from Bothrops pirajai venom]]></article-title>
<source><![CDATA[BMC complementary and alternative medicine]]></source>
<year>2012</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B43">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xuemin]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<source><![CDATA[Phospholipases. En Lipid Metabolism in Plants]]></source>
<year>2018</year>
<page-range>505-26</page-range><publisher-name><![CDATA[CRC Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B44">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Gong]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insight into Shared Properties and Differential Dynamics and Specificity of Secretory Phospholipase A2 Family Members]]></article-title>
<source><![CDATA[The Journal of Physical Chemistry B]]></source>
<year>2021</year>
<volume>125</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>3353-63</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
